Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Clinical pharmacology and therapyOpen Access

Treatment of primary IgA nephropathy Part 2. Immune suppressive therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

NBN. BulanovAEAnastasia EfimovaTBT Bochkareva

Discussion

Loading...

Member takes

Overview

Review highlights new immunosuppressive therapies for IgA nephropathy, suggesting personalized options may improve outcomes.

Key Points

  • Immunosuppressive therapy significantly reduces proteinuria and slows kidney function decline, improving long-term outcomes.
  • Systemic glucocorticoids decrease unfavorable disease outcomes short term, but come with risks of adverse events.
  • Emerging therapies like nefecon and complement inhibitors show high efficacy in treating IgA nephropathy.
  • Anti-B-cell therapy targeting BAFF and APRIL presents promising options, expanding treatment approaches for IgAN.

Cite This Study

Bulanov et al. (2025) studied this question.

synapsesocial.com/papers/68e24e65d6d66a53c2473507https://doi.org/10.32756/0869-5490-2025-3-5-12
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeted Therapeutic Options Based on the Pathogenesis of IgA Nephropathy2025 · 1 citations
  2. 2Immunoglobulin A nephropathy—novel insights in long-term outcomes and pathophysiology leading to international guideline modification and new emerging therapies2026
  3. 3IgA Nephropathy – Current and Future Perspectives in Treatment2024
  4. 4Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies2026
  5. 5Opportunities and challenges in the treatment of IgA nephropathy2025 · 3 citations